CAR T-Cell Therapy Feasible, Safe for Autoimmune Diseases
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 21, 2024 -- CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a study published in the Feb. 22 issue of the New England Journal of Medicine.
Fabian Müller, M.D., from the Friedrich-Alexander University Erlangen-Nürnberg in Germany, and colleagues examined patients with severe systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, or systemic sclerosis (eight, three, and four patients, respectively) who received a single infusion of CD19 CAR T-cells after fludarabine and cyclophosphamide preconditioning. Efficacy was assessed up to two years after CAR T-cell infusion, measured using the Definition of Remission in SLE (DORIS) remission criteria, American College of Rheumatology-European League against Rheumatism (ACR-EULAR) major clinical response, and the score on the European Scleroderma Trials and Research Group (EUSTAR) activity index.
Patients were followed for a median of 15 months. The mean duration of B-cell aplasia was 112 ± 47 days. The researchers found that all patients with SLE had DORIS remission, all patients with idiopathic inflammatory myositis had an ACR-EULAR major clinical response, and a reduction in the score on the EUSTAR activity index was seen for all patients with systemic sclerosis. In all patients, immunosuppressive therapy was completely stopped. In 10 patients, grade 1 cytokine release syndrome occurred.
"Even though it is premature to judge whether these patients are indeed cured from their autoimmune disease, CD19 CAR T-cells at least appear to be able to achieve sustained disease- and drug-free remission," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Air Pollutant Exposure Linked to Increased Risk for Incident Lupus
WEDNESDAY, July 10, 2024 -- Air pollutant exposure is associated with an increased likelihood of developing incident systemic lupus erythematosus (SLE), according to a study...
FDA Approves Belimumab Autoinjector for Pediatric Systemic Lupus Erythematosus
WEDNESDAY, May 22, 2024 -- The U.S. Food and Drug Administration has approved a 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and...
Neuropsychiatric Symptoms Can Present at Any Stage of Lupus
TUESDAY, May 21, 2024 -- For patients with systemic lupus erythematosus (SLE), neuropsychiatric (NP) symptoms can first present at any stage in the disease course, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.